These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 9803879)
21. Myeloma phenotype: clues to disease origin and manifestation. Epstein J Hematol Oncol Clin North Am; 1992 Apr; 6(2):249-56. PubMed ID: 1582972 [TBL] [Abstract][Full Text] [Related]
22. Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage. Yamashita T; Tamura H; Satoh C; Shinya E; Takahashi H; Chen L; Kondo A; Tsuji T; Dan K; Ogata K Clin Cancer Res; 2009 Feb; 15(3):770-7. PubMed ID: 19188146 [TBL] [Abstract][Full Text] [Related]
23. Constitutive expression of IL-6-LIKE cytokines in normal bone marrow: implications for pathophysiology of myeloma. Barton BE; Murphy TF Cytokine; 2000 Oct; 12(10):1537-45. PubMed ID: 11023670 [TBL] [Abstract][Full Text] [Related]
24. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Holt RU; Baykov V; Rø TB; Brabrand S; Waage A; Sundan A; Børset M Haematologica; 2005 Apr; 90(4):479-88. PubMed ID: 15820943 [TBL] [Abstract][Full Text] [Related]
25. Special Education: Aplastic Anemia. Teramura M; Mizoguchi H Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986 [TBL] [Abstract][Full Text] [Related]
26. Establishment of a human myeloma cell line with growth-promoting activity for bone marrow-derived fibroblastoid colony-forming cells. Takahira H; Kozuru M; Hirata J; Obama K; Uike N; Iguchi H; Miyamura T; Yamashita S; Kono A; Umemura T Exp Hematol; 1994 Mar; 22(3):261-6. PubMed ID: 8112425 [TBL] [Abstract][Full Text] [Related]
27. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Giuliani N; Colla S; Morandi F; Rizzoli V Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473 [TBL] [Abstract][Full Text] [Related]
28. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells. Li M; Cortez S; Nakamachi T; Batuman V; Arimura A Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196 [TBL] [Abstract][Full Text] [Related]
29. Paraproteinaemias: pathophysiology. Samson D Schweiz Med Wochenschr; 2000 Nov; 130(44):1643-8. PubMed ID: 11103434 [TBL] [Abstract][Full Text] [Related]
30. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177 [TBL] [Abstract][Full Text] [Related]
31. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Grigorieva I; Thomas X; Epstein J Exp Hematol; 1998 Jul; 26(7):597-603. PubMed ID: 9657134 [TBL] [Abstract][Full Text] [Related]
32. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Pellat-Deceunynck C; Barillé S; Puthier D; Rapp MJ; Harousseau JL; Bataille R; Amiot M Cancer Res; 1995 Aug; 55(16):3647-53. PubMed ID: 7543019 [TBL] [Abstract][Full Text] [Related]
33. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma]. Li J; Luo SK; Hong WD; Zhou ZH; Zou WY Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985 [TBL] [Abstract][Full Text] [Related]
34. Disseminated growth of murine plasmacytoma: similarities to multiple myeloma. Roschke V; Hausner P; Kopantzev E; Pumphrey JG; Riminucci M; Hilbert DM; Rudikoff S Cancer Res; 1998 Feb; 58(3):535-41. PubMed ID: 9458102 [TBL] [Abstract][Full Text] [Related]
35. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. Asosingh K; Günthert U; De Raeve H; Van Riet I; Van Camp B; Vanderkerken K Cancer Res; 2001 Apr; 61(7):2862-5. PubMed ID: 11306459 [TBL] [Abstract][Full Text] [Related]
36. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892 [TBL] [Abstract][Full Text] [Related]
37. Physician Education: Myelodysplastic Syndrome. Yoshida Y Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004 [TBL] [Abstract][Full Text] [Related]
38. [Myeloma precursor cells and their differentiation]. Kawano MM Nihon Rinsho; 1995 Mar; 53(3):552-6. PubMed ID: 7699884 [TBL] [Abstract][Full Text] [Related]
39. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Kline M; Donovan K; Wellik L; Lust C; Jin W; Moon-Tasson L; Xiong Y; Witzig TE; Kumar S; Rajkumar SV; Lust JA Leuk Res; 2007 May; 31(5):591-8. PubMed ID: 16879867 [TBL] [Abstract][Full Text] [Related]